CNS biomarkers from blood

Brain-derived biomarkers from a routine blood draw

NeuroDex’s ExoSORT™ platform isolates extracellular vesicles released into blood by brain cells, such as neurons and oligodendrocytes, to measure target engagement, pharmacodynamics and disease biology. Every assay runs in our CLIA-certified, GCLP-aligned laboratories in Natick, MA, from preclinical studies through clinical trials.

Why brain-derived

Why measure biomarkers inside brain-derived vesicles?

Blood markers like NfL tell you the brain is injured, not whether your drug reached its target. Proteins such as α-synuclein and TDP-43 are made throughout the body, so a plain plasma reading mixes brain and non-brain signal. ExoSORT™ enriches the vesicles that brain cells, such as neurons and oligodendrocytes, release into blood, so the readout reflects brain biology.

Phase 2b

Trial-proven

Neuron-derived TDP-43 measured in our lab was a registered primary outcome in the PARADIGM ALS trial (NCT05357950).

>80%

Checked against CSF

Sensitivity and specificity of neuron-derived α-synuclein for predicting CSF seeding-assay positivity (N=150 PD and LBD).

500 µL

Built for trials

EDTA plasma per sample, with reports typically 2–3 weeks after receipt.

40+

Backed by the field

Pharma and biotech collaborations, with funding from the Michael J. Fox Foundation, ADDF and Target ALS.

Brain-derived biomarker panels for CNS drug development

α-Syn
Biomarker

Neuronal α-synuclein from blood for Parkinson’s, MSA and Lewy body dementia. Supports patient stratification and target engagement.

TDP43
Biomarker

Neuron-derived TDP-43 for ALS and FTD. Tracks treatment response in TDP-43–targeted programs.

Tau/pTau
Biomarker

Neuronal tau and phospho-tau for Alzheimer’s disease. Measures tau changes at their source inside neurons.

NF-L
Biomarker

Neurofilament light, a marker of neuronal damage in brain injury and neuroinflammation. Tracks disease activity across programs.

LC3
Biomarker

LC3 and cathepsin D for autophagy–lysosome function. Shows whether a therapy engages the autophagy pathway in neurons.

NF-kB
Biomarker

Neuronal NF-κB signaling for neuroinflammation. Measures inflammatory pathway activity in neurons across diseases.

AKT panel
Biomarker

Insulin/AKT signaling in neurons. Measures CNS metabolic effects of therapies such as GLP-1 agonists.

Synaptic protein
Biomarker

Synaptic proteins as a readout of synaptic health and plasticity across neurodegenerative diseases.

Biomarker Discovery & Validation

Services

Find and qualify new CNS biomarkers in brain-derived vesicles, using immunoassays and RNA sequencing.

Translational Research Biomarkers

Services

Turn brain-derived biomarkers into endpoints your drug program can use, from preclinical models to first-in-human studies.

Brain-Derived Vesicle Isolation and Analysis

Services

ExoSORT™ isolation of brain-derived vesicles from plasma, followed by protein and RNA biomarker analysis.

Clinical Trial Biomarker Support

Services

Serial plasma testing at every study visit, for patient stratification, target engagement, pharmacodynamics and endpoint analysis.

Evidence

Funded, peer-reviewed and used in clinical trials

1,062+

Open dataset

Neuron-derived EV RNA-seq samples from about 356 PDBP participants, released in AMP PD Release 4.3.

About the dataset

1,304

Autopsy-validated

With Columbia University: α-synuclein in neuron-derived vesicles was elevated in Lewy body pathology confirmed at autopsy.

Read the study

GLP-1

CNS target engagement

With Stanford: first evidence of CNS target engagement for GLP-1 and PPARγ agonists from blood (JCEM, 2026).

Read the study

17

Peer-reviewed papers

Publications on brain-derived extracellular vesicles, from 2016 to 2026.

See publications

Biomarker services for CNS drug development

NeuroDex works with pharma and biotech teams from target validation through clinical trials. Our brain-derived extracellular vesicle panels give your program target-engagement, pharmacodynamic and stratification readouts from plasma, with no lumbar puncture, run in our CLIA-certified, GCLP-aligned laboratory.

Target engagement

Pharmacodynamics

CLIA & GCLP quality

Patient stratification

01

Parkinson's disease and synucleinopathy

α-synuclein for stratification and target engagement in synucleinopathy programs.

02

ALS

TDP-43 for ALS and FTD programs, including a Phase 2b primary outcome.

03

Alzheimer's disease

Tau/pTau and synaptic markers for Alzheimer’s drug programs.

04

Neuroinflammation

NF-κB pathway activity for anti-inflammatory CNS programs.

05

Autophagy, Brain injury

LC3 and cathepsin D for autophagy–lysosome programs.